272. 進行性骨化性線維異形成症 Fibrodysplasia ossificans progressiva Clinical trials / Disease details
臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002286-17-FR (EUCTR) | 19/04/2022 | 22/10/2021 | A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Fibrodysplasia ossificans progressiva MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Code: INCB000928 Other descriptive name: INCB000928 fumarate dihydrate | Incyte Corporation | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | United States;France;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Korea, Republic of | ||
| 2 | EUCTR2021-002286-17-DE (EUCTR) | 04/11/2021 | A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Fibrodysplasia ossificans progressiva MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Code: INCB000928 Other descriptive name: INCB000928 fumarate dihydrate | Incyte Corporation | NULL | NA | Female: yes Male: yes | 60 | Phase 2 | France;United States;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Korea, Republic of |